Aileron Therapeutics

52 articles with Aileron Therapeutics

• Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium

  10/20/2020

  Aileron Therapeutics (Nasdaq: ALRN) today announced that it will host a conference call and live webcast to discuss results from a Phase 1b proof-of-concept study of ALRN-6924 on Monday, October 26, 2020 at 8:30 a.m. ET

• Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium

  10/12/2020

  Aileron Therapeutics announced that proof-of-concept data from the company’s Phase 1b study of ALRN-6924 will be featured in a late-breaking poster presentation during the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics, being held virtually October 24 – 25, 2020.

• Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital

  9/21/2020

  Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $15 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor and current shareholder. In connection with the execution of the purchase agreement, LPC made an initial purchase of $500,000 of common stock at $1.36 per share. Thereafter, Aileron will have the optio

• Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference

  9/10/2020

  Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the upcoming H.C. Wainwright Virtual Global Investment Conference, including an update on the company’s efforts to advance chemoprotection for patients with p53-mutated cancers regardless of cancer type or chemotherapeutic drug. The presentation is scheduled for September 14, 2020

• Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/5/2020

  Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the second quarter ended June 30, 2020.

• Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August

  8/3/2020

  Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month. Thursday, August 6, 2020 Event: William Blair Biotech Focus Conference 2020 Time:  12:00 pm ET *Fireside chat Thursday, August 13, 2020 Event: Canaccord Genuity 40 th Annual Growth Conference Time:  4:30 pm ET *Company overview and business

• Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924

  8/3/2020

  Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan Previously reported positive interim data from dose optimization part of study demonstrated 0.3 mg/kg dose of ALRN-6924, now being evaluated in expansion cohort, resulted in most robust chemoprotective effects

• 

  Clinical Catch-Up: June 29-July 3

  7/6/2020

  Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
• 

  Clinical Catch-Up: May 25-29

  6/1/2020

  In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
• 

  Clinical Catch-Up: October 14-18

  10/21/2019

  Last week was busy for clinical trial news. Here’s a look.
• 

  Clinical Catch-Up: September 23-27

  9/30/2019

  It was a moderately busy week for clinical trial news. Here’s a look.
• 

  Movers and Shakers for Sept. 10

  9/10/2018

  Let's take a look at who made a splash in the pharma and biotech world the past week.
• 

  Is There a Biotech Bubble Brewing in Boston?

  3/21/2018

  Billions of dollars are being invested in Boston-based life science companies.
• 

  The 2017 Biotech IPO Winners and Losers

  12/21/2017

  Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.

• Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting

  12/12/2017

  The data were reviewed in separate oral presentations by researchers from the Dana-Farber Cancer Institute and the Albert Einstein College of Medicine during the 2017 American Society of Hematology Annual Meeting.

• Aileron Therapeutics Reports Third Quarter 2017 Financial Results

  11/10/2017

  Cash, cash equivalents and investments as of September 30, 2017 were $56.9 million, compared to $20.7 million as of December 31, 2016.

• Aileron Therapeutics Added To The Russell 2000, Russell 3000 And Russell Microcap Indexes

  9/19/2017

• Aileron Therapeutics Announces Presentation Of Preclinical Data With ALRN-6924 At The International Society Of Experimental Hematology Annual Scientific Meeting

  8/24/2017

• Aileron Therapeutics Reports Second Quarter 2017 Financial Results

  8/11/2017

• Aileron Therapeutics Announces Pricing Of Initial Public Offering

  6/29/2017